The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) represent the standard of care as first-line treatment for patients with non-small-cell lung cancer (NSCLC) harbouring EGFR mutation. There are few treatment options after progression from TKI. In the absence of targetable mutations, patients who develop resistance are usually treated with chemotherapy. There are limited data focusing the role of TKI re-treatment. We present the case of a patient who achieved clinical benefit and objective response upon re-treatment with a first-generation anti-EGFR TKI.
Effective tyrosine kinase inhibitor re-treatment in epidermal growth factor receptor-mutated non-small-cell lung cancer patient. A case report / Galletti, Alessandro; Russano, Marco; Citarella, Fabrizio; Vincenzi, Bruno; Tonini, Giuseppe; Santini, Daniele. - In: PRECISION CANCER MEDICINE. - ISSN 2617-2216. - 3:December(2020), pp. 29-29. [10.21037/pcm-20-56]
Effective tyrosine kinase inhibitor re-treatment in epidermal growth factor receptor-mutated non-small-cell lung cancer patient. A case report
Santini, Daniele
2020
Abstract
The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) represent the standard of care as first-line treatment for patients with non-small-cell lung cancer (NSCLC) harbouring EGFR mutation. There are few treatment options after progression from TKI. In the absence of targetable mutations, patients who develop resistance are usually treated with chemotherapy. There are limited data focusing the role of TKI re-treatment. We present the case of a patient who achieved clinical benefit and objective response upon re-treatment with a first-generation anti-EGFR TKI.File | Dimensione | Formato | |
---|---|---|---|
Galletti_Effective_2020.pdf
accesso aperto
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
275.15 kB
Formato
Adobe PDF
|
275.15 kB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.